Stock Research Monitor: SRRA, ONCE, and SPPI
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. US markets saw five out of nine sectors finishing the day in red and four in green. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Thursday, shares in Vancouver, Canada headquartered Sierra Oncology Inc. recorded a trading volume of 258,394 shares. The stock ended at $2.32, declining 1.69% from the last trading session. The Company's shares have gained 26.78% in the last month and 90.16% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 8.88% and 0.18%, respectively. Furthermore, shares of Sierra Oncology, which researches, develops, and commercializes DNA Damage Response therapeutics for the treatment of patients with cancer in the US and internationally, have a Relative Strength Index (RSI) of 53.02. Get the full research report on SRRA for free by clicking below at:
San Diego, California-based Sorrento Therapeutics Inc.'s stock finished yesterday's session 5.30% higher at $7.95. A total volume of 1.63 million shares was traded. The Company's shares have gained 30.33% in the last month and 381.82% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 20.28% and 74.55%, respectively. Furthermore, shares of Sorrento Therapeutics, which engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide, have an RSI of 65.33. Today's complimentary research report on SRNE is accessible at:
At the close of trading on Thursday, shares in Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc. saw a rise of 1.05%, ending the day at $79.02. The stock recorded a trading volume of 324,104 shares. The Company's shares have advanced 43.62% in the previous three months and 43.15% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 9.46% and 12.96%, respectively. Moreover, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 58.97.
On May 09th, 2018, research firm Barclays reiterated its ‘Overweight' rating on the Company's stock with an increase of the target price from $64 a share to $85 a share. Sign up for free on Wall St. Equities and claim the latest report on ONCE at:
Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc.'s shares ended the day 2.10% lower at $19.10 with a total trading volume of 1.12 million shares. The stock has gained 12.29% in the last month and 213.63% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 8.23% and 12.46%, respectively. Additionally, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have an RSI of 57.84. See the free research coverage on SPPI at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities